Does Pacific Edge have a target on its back?

Does Pacific Edge have a target on its back?
Invested capital in Cxbladder makes for an 'attractive acquisition target' (Image: supplied)
Brent Melville
Cancer diagnostic company Pacific Edge could be ripe for a takeover, analysis by investment firm Bell Potter suggests.Bell Potter, the Australian adviser to Pacific Edge’s September listing on the ASX, kicked off coverage of the Dunedin-based company with a speculative buy recommendation this week, valuing it at A$1.10 ($1.19) a share. That’s an 18% premium to Tuesday’s ASX price of 93 Australian cents, and a firm advance on its NZX Tuesday close of 99 cents. Local investment house Jarden pegs the NZX target price at $1.1...

More Markets

Ryman, Fletcher lift as market ends 9-day winning streak
Markets

Ryman, Fletcher lift as market ends 9-day winning streak

Market down despite Fletcher Building and Ryman Healthcare rising.

Allied Farmers shareholders back sale of NZ Farmers Livestock
Primary Sector

Allied Farmers shareholders back sale of NZ Farmers Livestock

Allied will hold $14m in reserves as it looks for its next investment opportunity.

BNZ profit dips as economic return proves sluggish
Finance

BNZ profit dips as economic return proves sluggish

Net-interest margin tiptoes higher but total operating income slips. 

Commerce Commission approves Huntly agreement
Markets

Commerce Commission approves Huntly agreement

Gentailer deal to keep Rankine unit running gets a quick tick.